CAS: 21211-07-4; Methyl 3-Chlorobenzo[b]Thiophene-2-Carboxylate

上下游产品

methanol 3-chlorobenzo[b]thiophen-2-carbonyl chloride methyl (2Z)-3-phenylprop-2-enoate Cinnamic acidthiophene3-chloro-2-hydrazin°Carbonylbenzothiophene methyl benzo[b]thiophene-2-carboxylate 3-chloro-1-benzothiophene-2-carboxylic acid 1-Carboxymethoxy-3,8-dithia-cyclopenta[a]indene-2-carboxylic acid2,3-dichloro-pyridine methanol carbon monoxide

📜Methyl (2Z)-3-Phenylprop-2-Enoate置于吡啶,氯化亚砜体系中,化学反应 0.5H,以92%的收率获得3-氯苯并噻吩-2-羧酸甲酯
参考文献:Ried,Walter; Oremek,Gerhard; ocakcioglu,Belkis,Liebigs Annalen Der Chemie,1980,# 9,P. 1424-1427
标题:Ried,Walter; Oremek,Gerhard; ocakcioglu,Belkis,Liebigs Annalen Der Chemie,1980,# 9,P. 1424-1427

专利信息

专利号:US-2010035867-A1
优先权日:2006-07-11
标 题 :Inhibitors of Cyclic Nucleotide Synthesis and Their Use for Therapy of Various Diseases
发明人：GUERRANT RICHARD L; KOTS ALEXANDER Y; MURAD FERID; CHOI BYUNG-KWON
权利人:GUERRANT RICHARD L; KOTS ALEXANDER Y; MURAD FERID; CHOI BYUNG-KWON
摘要:We disclose a method of inhibiting activity of adenylyl cyclase or guanylyl cyclase in a mammal by administering to the mammal an amount of a composition effective to inhibit the activity, wherein the composition contains at least one compound selected from the group consisting of structural formulae (Ia) and (Ib) and salts thereof, wherein R1 is —H or has the structure —C(â•?O)R8; R2 is â•?O or has the structure —OC(â•?O)R9; and R3, R4, R5, R6, and R7 are each independently selected from the group consisting of —H, —NO 2 , formula (I), -halogen, —OC(â•?O)R9, —OR9, —OH, —R8OH, —CH 3 , —OC(â•?O)CH 2 Ph, formulae (II), (III), (IV), —OPh, —CF 3 , —R8, —C(â•?O)OR9, -Ph, —R8Ph, formulae (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), (XVII), (XVIII), (XIX), (XX), and (XXI), wherein each R8 is independently a linear or branched hydrocarbon group having from 1 to 4 carbon atoms and each R9 is independently a hydrocarbon group having from 1 to 2 carbon atoms. Administering the composition can be used to treat a disease in a mammal mediated by activity of adenylyl cyclase or guanylyl cyclase and effected by a toxin produced by a pathogenic organism or to reduce cyclic AMP or cyclic GMP levels in a mammal in need of reduction thereof. The composition can also be administered to mammalian cells in vitro. The above methods of inhibiting activity of adenylyl cyclase or guanylyl cyclase and treating diseases via such inhibition can be effective without prolonged treatment, have reversible effects, have low or no toxicity, are highly potent, are unlikely to have side effects, do not act on purinergic recptors, or can negate pathogenic toxins independently of whether the pathogenic organism survives.